CRESTOR is a member of the statin class; for the treatment of dyslipidaemia. CRESTOR reduces LDL-C (‘bad’ cholesterol) and raises HDL-C (‘good’ cholesterol).CRESTOR was initially developed by the Japanese pharmaceutical company Shionogi and in-licensed to AstraZeneca in April 1998.For rosuvastatin clinical information please visit www.rosuvastatininformation.com
Did you know?
AstraZeneca has a range of product specific and disease area websites for international healthcare professionals and patients. Links to this information can be found below.
Links to country-specific websites can be found using the AstraZeneca websites list.
If you still have a question regarding our drug portfolio you can Contact us.
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD - Stockholm
-
310.10 SEK
At Nov 21, 2009 4:47 AM GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
